As previously reported, JPMorgan upgraded Bruker to Overweight from Neutral with a price target of $90, up from $60, after the company reported a “sizeable” Q4 beat and gave “strong,” better-than-expected 2024 guidance. Most notably, the company pulled forward its 2026 revenue and non-GAAP EPS targets to 2025, which points to sustainable demand and competitive positioning, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRKR:
- Bruker Corp Announces Senior Notes Issuance for Corporate Financing
- Bruker Corp Secures CHF 100M in Senior Notes for Growth and Refinancing
- Bruker Corp Announces Private Offering and Financial Strategy
- Bruker announces the acquisition of Japan-based Nanophoton, no terms
- Bruker acquires Spectral Instruments Imaging
